[HTML][HTML] Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial
Introduction Older adults are subject to higher COVID-19 infection and mortality rates. Safety
and immunogenicity of MVC-COV1901, a protein subunit vaccine have been demonstrated …
and immunogenicity of MVC-COV1901, a protein subunit vaccine have been demonstrated …
Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial
A Waits, JY Chen, WH Cheng, JI Yeh… - … Journal of Infectious …, 2022 - hub.tmu.edu.tw
Introduction: Older adults are subject to higher COVID-19 infection and mortality rates.
Safety and immunogenicity of MVC-COV1901, a protein subunit vaccine have been …
Safety and immunogenicity of MVC-COV1901, a protein subunit vaccine have been …
Safety and immunogenicity of MVC-COV1901 vaccine in older adults: phase 2 randomized dose-comparison trial.
A Waits, JY Chen, WH Cheng, JI Yeh, SM Hsieh… - 2022 - cabidigitallibrary.org
Introduction: Older adults are subject to higher COVID-19 infection and mortality rates.
Safety and immunogenicity of MVC-COV1901, a protein subunit vaccine have been …
Safety and immunogenicity of MVC-COV1901, a protein subunit vaccine have been …
Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial
A Waits, JY Chen, WH Cheng, JI Yeh… - … Journal of Infectious …, 2022 - tcu.elsevierpure.com
摘要Introduction: Older adults are subject to higher COVID-19 infection and mortality rates.
Safety and immunogenicity of MVC-COV1901, a protein subunit vaccine have been …
Safety and immunogenicity of MVC-COV1901, a protein subunit vaccine have been …
Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial
A Waits, JY Chen, WH Cheng, JI Yeh… - International Journal of …, 2022 - ijidonline.com
Introduction Older adults are subject to higher COVID-19 infection and mortality rates. Safety
and immunogenicity of MVC-COV1901, a protein subunit vaccine have been demonstrated …
and immunogenicity of MVC-COV1901, a protein subunit vaccine have been demonstrated …
[HTML][HTML] Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial
A Waits, JY Chen, WH Cheng, JI Yeh… - … Journal of Infectious …, 2022 - ncbi.nlm.nih.gov
Methods A double-blind, randomized, multi-center study compared safety and
immunogenicity of high-dose (25 mcg) to mid-dose (15 mcg) of MVC-COV1901 …
immunogenicity of high-dose (25 mcg) to mid-dose (15 mcg) of MVC-COV1901 …
Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial
A Waits, JY Chen, WH Cheng, JI Yeh… - … Journal of Infectious …, 2022 - pure.lib.cgu.edu.tw
Introduction: Older adults are subject to higher COVID-19 infection and mortality rates.
Safety and immunogenicity of MVC-COV1901, a protein subunit vaccine have been …
Safety and immunogenicity of MVC-COV1901, a protein subunit vaccine have been …
Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial.
A Waits, JY Chen, WH Cheng, JI Yeh… - … Journal of Infectious …, 2022 - europepmc.org
Methods A double-blind, randomized, multi-center study compared safety and
immunogenicity of high-dose (25 mcg) to mid-dose (15 mcg) of MVC-COV1901 …
immunogenicity of high-dose (25 mcg) to mid-dose (15 mcg) of MVC-COV1901 …
Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial
A Waits, JY Chen, WH Cheng, JI Yeh… - … publication of the …, 2022 - pubmed.ncbi.nlm.nih.gov
Introduction Older adults are subject to higher COVID-19 infection and mortality rates. Safety
and immunogenicity of MVC-COV1901, a protein subunit vaccine have been demonstrated …
and immunogenicity of MVC-COV1901, a protein subunit vaccine have been demonstrated …
Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial
A Waits, JY Chen, WH Cheng, JI Yeh… - … Journal of Infectious …, 2022 - hub.tmu.edu.tw
摘要Introduction: Older adults are subject to higher COVID-19 infection and mortality rates.
Safety and immunogenicity of MVC-COV1901, a protein subunit vaccine have been …
Safety and immunogenicity of MVC-COV1901, a protein subunit vaccine have been …